- PolyPeptide Group and Lupin Manufacturing Solutions have entered a strategic alliance to improve supply chain resilience and support long-term growth.
- The collaboration includes integrated procurement and supply planning for select raw materials required in peptide manufacturing.
PolyPeptide Group has formed a strategic alliance with Lupin Manufacturing Solutions Limited to enhance supply chain resilience and operational efficiency for peptide-based active pharmaceutical ingredients. The companies said the agreement will broaden PolyPeptide’s sourcing options for key materials and create a more flexible supply chain structure.
The alliance establishes a framework for long-term cooperation, covering integrated procurement and supply planning for selected raw materials. Both organisations stated that the partnership reflects a shared commitment to quality, reliability, and compliance within peptide manufacturing.
“The collaboration supports growing customer demand. Working with Lupin Manufacturing Solutions gives us the flexibility and supply chain depth needed to support growing customer demand, including metabolics demand.”
Dr Stéphane Varray, Chief Commercial Officer at PolyPeptide
“The partnership aligns with the company’s mission to ensure reliable access to specialised materials for commercial-scale production. The peptide-based therapies are influencing the treatment of metabolic and other chronic conditions and require secure and agile manufacturing pathways.”
Lupin Manufacturing Solutions Chief Executive Officer Dr Abdelaziz Toumi
The companies stated that the alliance strengthens their respective positions in the peptide manufacturing value chain and supports long-term development strategies for both parties.
